163 reports of this reaction
1.6% of all VIBEGRON reports
#17 most reported adverse reaction
PRODUCT AVAILABILITY ISSUE is the #17 most commonly reported adverse reaction for VIBEGRON, manufactured by Sumitomo Pharma America, Inc.. There are 163 FDA adverse event reports linking VIBEGRON to PRODUCT AVAILABILITY ISSUE. This represents approximately 1.6% of all 10,281 adverse event reports for this drug.
Patients taking VIBEGRON who experience product availability issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT AVAILABILITY ISSUE is a less commonly reported adverse event for VIBEGRON, but still significant enough to appear in the safety profile.
In addition to product availability issue, the following adverse reactions have been reported for VIBEGRON:
The following drugs have also been linked to product availability issue in FDA adverse event reports:
PRODUCT AVAILABILITY ISSUE has been reported as an adverse event in 163 FDA reports for VIBEGRON. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT AVAILABILITY ISSUE accounts for approximately 1.6% of all adverse event reports for VIBEGRON, making it a notable side effect.
If you experience product availability issue while taking VIBEGRON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.